People with breast cancer are a step closer to knowing if their tumour is responding to chemotherapy at the start of treatment, thanks to a $100,000 catalyst grant from the Ontario Institute for Cancer Research (OICR).
Venaxis, Inc. (NASDAQ:APPY), an in vitro diagnostic company focused on obtaining FDA clearance for and commercializing its CE Marked APPY1™ Test, a rapid, multiple biomarker-based index assay for identifying patients that are at low risk for appendicitis, recently announced the closing of its previously announced underwritten public offering of 8,335,000 shares of its common stock at a price to the public of $2.40 per share. In addition, Venaxis has granted the underwriters a 30-day option to purchase up to an additional 1,250,250 shares of common stock solely to cover over-allotments, if any.
NanoString Technologies Introduces Novel PanCancer Gene Expression Panel for Multiplexed Pathway Analysis
NanoString Technologies, Inc., (NASDAQ:NSTG) a provider of life science tools for translational research and molecular diagnostic products, recently announced the launch of the nCounter® PanCancer Pathways Panel, a highly-multiplexed, digital gene expression assay that offers a unique way for translational researchers to investigate cancer biology across all major cancer pathways. The company made the announcement at the 105th Annual Meeting of the American Association for Cancer Research (AACR) in San Diego.
GE Healthcare, a unit of General Electric Company (NYSE: GE), recently announced that it received U.S. FDA 510(k) clearance of its Q.Clear^ technology – technology that can provide up to two times improvement in both quantitative accuracy and image quality in PET/CT imaging. This is an innovative new tool for clinicians across the entire care continuum including diagnosis, staging, treatment planning, and treatment assessment.
Private Australian biotechnology company Minomic International Ltd will launch two overseas trials of its MiStat™ prostate cancer screening test, following an agreement with the prestigious CUSP Group, LLC a Uro-Oncology Trials Management Organisation in the United States.